Atossa Therapeutics (ATOS) Change in Accured Expenses (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Change in Accured Expenses of -$615000.0 for Q1 2026, down 2773.91% year-over-year from $23000.0 in Q1 2025, and up 58.45% quarter-over-quarter from -$1.5 million in Q4 2025.
Atossa Therapeutics (ATOS) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Change in Accured Expenses for 16 consecutive years, with -$615000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 2773.91% year-over-year to -$615000.0; the TTM figure through Mar 2026 stood at -$1.0 million (down 254.05% YoY), while the FY2025 annual figure was -$410000.0, down 38.51% from the prior year.
- Change in Accured Expenses grew to -$615000.0 in Q1 2026 per ATOS's latest filing, from -$1.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.0 million in Q3 2025 and bottomed at -$1.5 million in Q4 2025.
- Historically, Change in Accured Expenses has averaged -$70235.3 across 5 years, with a median of $23000.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses sank 3784.21% — and 2025, when it surged 736.89%.
- Atossa Therapeutics' Change in Accured Expenses stood at $111000.0 in 2022, then sank by 165.77% to -$73000.0 in 2023, then surged by 506.85% to $297000.0 in 2024, then plunged by 598.32% to -$1.5 million in 2025, then jumped by 58.45% to -$615000.0 in 2026.
- Business Quant data shows ATOS's Change in Accured Expenses at -$615000.0 in Q1 2026, -$1.5 million in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | -2.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.09 Mn |
| Jun 30, 2026 | -2.09 Mn |
| Mar 31, 2026 | -615,000.00 |
| Mar 31, 2026 | -615,000.00 |
| Dec 31, 2025 | -1.48 Mn |
| Dec 31, 2025 | -1.48 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 297,000.00 |
| Dec 31, 2024 | 297,000.00 |
| Sep 30, 2024 | 122,000.00 |
| Sep 30, 2024 | 122,000.00 |
| Jun 30, 2024 | -738,000.00 |
| Jun 30, 2024 | -738,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |